Evidence map›Paper›PMID 32907879›Full record

ArticleThe Journal of biological chemistry2020

Proteolytic cleavage of Podocin by Matriptase exacerbates podocyte injury.

Shota Ozawa, Masaya Matsubayashi, Hitoki Nanaura, Motoko Yanagita, Kiyoshi Mori, Katsuhiko Asanuma, Nobuyuki Kajiwara, Kazuyuki Hayashi, Hiroshi Ohashi, Masato Kasahara and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Cytoskeleton Rearrangement in Podocytopathies: An Update.International journal of molecular sciences · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Shota OzawaTMK Project at the Medical Innovation Center, Kyoto University, Kyoto, Japan; Research Unit/Innovative Medical Science, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan.
Masaya MatsubayashiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Hitoki NanauraDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Motoko YanagitaTMK Project at the Medical Innovation Center, Kyoto University, Kyoto, Japan; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan.
Kiyoshi MoriTMK Project at the Medical Innovation Center, Kyoto University, Kyoto, Japan; Department of Molecular and Clinical Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Katsuhiko AsanumaTMK Project at the Medical Innovation Center, Kyoto University, Kyoto, Japan; Department of Nephrology, Chiba University, Chiba, Japan.
Nobuyuki KajiwaraDepartment of Nephrology, Ikeda City Hospital, Ikeda, Osaka, Japan.
Kazuyuki HayashiDepartment of Nephrology, Ikeda City Hospital, Ikeda, Osaka, Japan.
Hiroshi OhashiDepartment of Pathology, Ikeda City Hospital, Ikeda, Osaka, Japan.
Masato KasaharaInstitute for Clinical and Translational Science, Nara Medical University, Kashihara, Nara, Japan.
Hideki YokoiDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroaki KataokaDepartment of Pathology, University of Miyazaki, Kihara, Miyazaki, Japan.
Eiichiro MoriDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan. Electronic address: emori@naramed-u.ac.jp.
Takahiko NakagawaTMK Project at the Medical Innovation Center, Kyoto University, Kyoto, Japan; Department of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan. Electronic address: nakagawt@gmail.com.
Nara Medical University · JPIkeda Municipal Hospital · JPKyoto University · JPChiba University · JPMitsubishi Group (Japan) · JPUniversity of Miyazaki · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Podocyte injury is a critical step toward the progression of renal disease and is often associated with a loss of slit diaphragm proteins, including Podocin. Although there is a possibility that the extracellular domain of these slit diaphragm proteins can be a target for a pathological proteolysis, the precise mechanism driving the phenomenon remains unknown. Here we show that Matriptase, a membrane-anchored protein, was activated at podocytes in CKD patients and mice, whereas Matriptase inhibitors slowed the progression of mouse kidney disease. The mechanism could be accounted for by an imbalance favoring Matriptase over its cognate inhibitor, hepatocyte growth factor activator inhibitor type 1 (HAI-1), because conditional depletion of HAI-1 in podocytes accelerated podocyte injury in mouse model. Matriptase was capable of cleaving Podocin, but such a reaction was blocked by either HAI-1 or dominant-negative Matriptase. Furthermore, the N terminus of Podocin, as a consequence of Matriptase cleavage of Podocin, translocated to nucleoli, suggesting that the N terminus of Podocin might be involved in the process of podocyte injury. Given these observations, we propose that the proteolytic cleavage of Podocin by Matriptase could potentially cause podocyte injury and that targeting Matriptase could be a novel therapeutic strategy for CKD patients.

Indexed as

ProteolysisAnimalsHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsMiceMice, KnockoutPodocytesProteinase Inhibitory Proteins, SecretoryProtein DomainsRenal Insufficiency, ChronicSerine EndopeptidasesIntracellular Signaling Peptides and ProteinsmatriptaseMembrane ProteinsNPHS2 proteinProteinase Inhibitory Proteins, SecretorySerine EndopeptidasesSpint1 protein, mousechronic kidney diseasediabetic nephropathyhepatocyte growth factor activator inhibitor type 1kidneyMatriptasePodocinpodocyteproteaseprotease inhibitor

Identifiers

PMID32907879
PMCPMC7681011
OpenAlexW3084372779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.